AzTrials
AzTrials

Early-onset SchizophreniaNCT05577338

ToM Psychotherapy and Brain Networks in EOS

A study testing Theory of Mind psychotherapy and health education in people with Early-onset Schizophrenia, run by The First Affiliated Hospital of Anhui Medical University at 1 site in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Background: Presence of a series of typical physical symptoms is an enduring and functionally relevant feature of early-onset schizophrenia (EOS). Psychotherapy improves clinical symptoms in adults with schizophrenia, although data in adolescents with EOS remain scarce. Read more about this study

Who is it for?
Ages 13 to 18 years
Conditions the study is for
Early-onset Schizophrenia
What is being tested?
Theory of Mind psychotherapy and health education
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
1 siteChina
Study dates
1 Aug 2018to 30 Sep 2021
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 13 to 18 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Who may be able to join

  • Clinical diagnosis of EOS
  • Right-handed subjects
  • Aged 13 - 18 years old
  • Capable of understanding, judgments and expression

Who cannot join

  • The presence of other psychiatric disorders such as substance-induced mood disorder, bipolar disorders, anxiety disorders, substance abuse, or dependence
  • A history of significant physical or neurological disease
  • A history of head injury with loss of consciousness
  • A history of electroconvulsive therapy
  • Contraindications for MRI such as claustrophobia
  • Mental retardation.

Trial locations and contacts

1 site in 1 country.

China1 site
  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, 230022

Other trials in China

About this study

Official title: Neural Mechanism Underlying the Beneficial Effect of Theory of Mind Psychotherapy on Early-onset Schizophrenia: A Randomized Controlled Trial.

Background: Presence of a series of typical physical symptoms is an enduring and functionally relevant feature of early-onset schizophrenia (EOS). Psychotherapy improves clinical symptoms in adults with schizophrenia, although data in adolescents with EOS remain scarce. The purpose of this study is to examine the efficacy of the adapted group psychotherapy in improving clinical symptoms from a perspective of neuroimaging in a sample of symptomatically stable adolescents with EOS.

Methods: Investigators conducted a double-blind randomized controlled trial using multidomain, adaptive, group psychotherapy in 28 EOS patients, who were randomly allocated into either training (group psychotherapy) or active control (health education) groups. Data of diffusion tensor imaging, and clinical symptoms were obtained at baseline and after an average of 2 hours/day, 2 days/week for 4 weeks of intervention.

Read the detailed description

Schizophrenia is a chronic psychiatric disorder with a heterogeneous genetic and neurobiological background that influences early brain development and is expressed as a combination of psychotic symptoms - such as hallucinations, delusions and disorganization - and motivational and cognitive dysfunctions. Schizophrenia occurs worldwide, and for decades it was generally believed to have a uniform lifetime morbid risk of 1% across time, geography, and gender. Characteristic, a substantial proportion of patients with schizophrenia experience the onset of their illness by age 18, defined as early-onset schizophrenia (EOS) and were found to be associated with higher rates of premorbid abnormalities, worse cognitive performance and worse functional outcome compared to individuals with adult-onset schizophrenia. Recently, EOS patients have been the focus of substantial interest, since studies of patients with adolescent onset could provide insights into the development of the disorder, in particular the interaction between normal maturational processes and the disorder. Furthermore, EOS is featured as a debilitating form of schizophrenia that has poor prognosis and functional outcomes and that places heavy demands on caregivers.

To the best of investigators' knowledge that enduring cognitive impairment is a core feature of the illness that predict chronicity and contribute to poor functional outcomes. As EOS is potentially a key stage at which early intervention may delay or prevent the poor outcomes, and pharmacological interventions have a limited effect on cognitive impairment in EOS patients, there is a critical need and growing interest in psychosocial interventions for effective treatments for cognitive impairment in young persons with this condition, which are now recognized as an important component of a comprehensive therapeutic approach in schizophrenia. Recent advances in cognitive training, however, may inform strategies to treat EOS. For instance, as cognitive remediation therapy (CRT) uses scientific principles of learning to target cognitive deficits with the ultimate goal of improving functional outcome, there is now a substantial body of evidence in support of its efficacy in adults with schizophrenia. Furthermore, the adult recommendations are adopted in clinical practice for the treatment (referring to group psychotherapy in this study) of children and adolescents with psychosis, as there is a paucity of studies conducted exclusively with EOS patients.

The notion that specific cognitive and social abilities arise from functionally distinct brain regions has been proved by means of multimodal neuroimaging techniques mainly including structural and functional Magnetic Resonance Imaging (MRI). Previous studies of EOS patients have found abnormalities in white matter microstructure, slower white matter growth rates and disrupted functional connectivity in brain networks involved in sensorimotor processing, social cognitions and executive functions. The abovementioned evidence supports the neurodevelopmental and dis-connectivity hypotheses of schizophrenia, but the specific pattern of abnormal brain structural connectivity in EOS remains scarce. Graph-theory analysis, which examines the important properties of complex systems (i.e., centrality, global efficiency, local efficiency and small-world property), is a useful tool to quantify the topology of abnormal brain networks in EOS. To our knowledge, using the graph-based network approach, previous research has mapped structural networks in adult patients with schizophrenia based on across-subject covariance in morphological indexes, such as cortical thickness, gyrification and grey matter volumes. However, in this context, investigators constructed structural connections of brain networks characterized by white matter integrity measured by diffusion tensor imaging (DTI). Moreover, it remains unclear that how brain structural topology is altered in EOS patients after the intervention of group psychotherapy.

In this study, investigators conducted an adaptable randomized controlled trial (RCT) to investigate the effects of group psychotherapy on brain structural connectivity in EOS patients using a graph-based approach of DTI. Investigators hypothesized that adaptable group psychotherapy would help to preserve brain structural network connectivity in addition to better ameliorating clinical symptoms.

Being tested
Theory of Mind psychotherapy, health education

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Theory of Mind psychotherapyBehavioural

    a semi-structured, multidomain, tailored group psychotherapy

  • health educationBehavioural

    disease-related health knowledge

Study groups in NCT05577338
Study groupRoleWhat they receive
training groupExperimentalTheory of Mind psychotherapy psychotherapy
Receives: Behavioral: Theory of Mind psychotherapy
active control groupActive comparatorreceive disease-related health knowledge
Receives: Behavioral: health education

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. changes in positive and negative scale score (PANSS)

    A standardized rating scale of clinical questionnaires without units designed to assess the severity of symptoms of different types of schizophrenia.

    Measured: Change from Baseline PANSS at 1 month

  2. changes in binary betweenness centrality

    One of the brain structural network properties computed via the software packages Brain functional Magnetic Resonance Imaging (FMRIB) Software Library (FSL3) and Diffusion Toolkit (DTK4) without units and captures the extent to which a node is in-between several other nodes in a network.

    Measured: Change from Baseline binary betweenness centrality at 1 month

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Oct 2022
  2. Study start1 Aug 2018
  3. Primary completion30 Aug 2021
  4. Study completion30 Sep 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
30 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05577338
Sponsor's protocol ID
PJ2022-10-37
Status last verified
Aug 2021
First submitted
19 Sep 2022
Last updated
13 Sep 2023
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Kumra S, Charles Schulz S. Editorial: research progress in early-onset schizophrenia. Schizophr Bull. 2008 Jan;34(1):15-7. doi: 10.1093/schbul/sbm123. Epub 2007 Nov 28.

    PubMed 18048380
  • Vernal DL, Boldsen SK, Lauritsen MB, Correll CU, Nielsen RE. Long-term outcome of early-onset compared to adult-onset schizophrenia: A nationwide Danish register study. Schizophr Res. 2020 Jun;220:123-129. doi: 10.1016/j.schres.2020.03.045. Epub 2020 Apr 13.

    PubMed 32299717
  • Armando M, Pontillo M, Vicari S. Psychosocial interventions for very early and early-onset schizophrenia: a review of treatment efficacy. Curr Opin Psychiatry. 2015 Jul;28(4):312-23. doi: 10.1097/YCO.0000000000000165.

    PubMed 26001923
  • Puig O, Penades R, Baeza I, De la Serna E, Sanchez-Gistau V, Bernardo M, Castro-Fornieles J. Cognitive remediation therapy in adolescents with early-onset schizophrenia: a randomized controlled trial. J Am Acad Child Adolesc Psychiatry. 2014 Aug;53(8):859-68. doi: 10.1016/j.jaac.2014.05.012. Epub 2014 Jun 21.

    PubMed 25062593
  • Liu S, Zhong H, Qian Y, Cai H, Jia YB, Zhu J. Neural mechanism underlying the beneficial effect of Theory of Mind psychotherapy on early-onset schizophrenia: a randomized controlled trial. J Psychiatry Neurosci. 2023 Nov 7;48(6):E421-E430. doi: 10.1503/jpn.230049. Print 2023 Nov-Dec.

    PubMed 37935475

Questions about this trial

What is this clinical trial studying?

A study testing Theory of Mind psychotherapy and health education in people with Early-onset Schizophrenia, run by The First Affiliated Hospital of Anhui Medical University at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 13 Sep 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

changes in positive and negative scale score (PANSS) (time frame: Change from Baseline PANSS at 1 month). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05577338, which also lists 5 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Sep 2023.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in